Ophthotech Corporation Company Profile
Ophthotech Corporation is a privately held biopharmaceutical company based in Princeton, NJ focused on developing and commercializing therapies for dry and wet AMD. Ophthotech is developing a pipeline of compounds with strong scientific foundations for the treatment of AMD, with the goal of bringing them to market in an accelerated manner. Ophthotechâs venture investors include SV Life Sciences Advisers, Novo Ventures, HBM Partners and Clarus Ventures. For more information, please visit www.ophthotech.com.
News Articles
PRINCETON, N.J.--(BUSINESS WIRE)--Oct 24, 2012 - Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech's FovistaTM an...
Ophthotech receives $36 million funding and inlicenses macular degeneration compounds
Ophthotech Corporation has completed a Series A financing of $36 million and two in-licensing deals for compounds for macular degeneration. Ophthotech and Archemix Corporation have established an excl...
Ophthotech to Present at 31st Annual J.P. Morgan Healthcare Conference
Ophthotech Corp. announced today that the company will participate in the 31st Annual J.P. Morgan Healthcare Conference to be held Jan. 7-10, 2013. Samir Patel, M.D., president an...
Ophthotech Nabs $175M To Fund Late-Stage Trial For Eye Drug
Ophthotech was founded by former Eyetech Pharmaceuticals executives to change the standard of care for the “wet” form of age-related macular degeneration: the leading cause of blindness among adul...
Ophthotech raises $58.3 million for AMD
Ophthalmic company Ophthotech Corp. (New York, N.Y.) raised $58.3 million on Wednesday, including the first $16.7 million tranche of a planned $50 million series C round from existing investors Novo A...
Ophthotech raises $175m for Fovista Phase III in wet AMD
Ophthotech raised $175 million, mostly in the form of royalty financing from Novo A/S, to fund a 1,900-patient Phase III clinical trial for its anti-platelet-derived growth factor (anti-PDGF) aptamer...
Ophthotech announces data from Fovista Phase 2b trial on wet AMD
Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech's Fovista anti-PDGF therapy (1.5 mg) in patients with neovascul...
Ophthotech raises $175M for phase III Fovista anti-PDGF combo therapy in wet AMD
Ophthotech, a privately held biopharmaceutical company, has raised $175 million to finance a global phase III clinical program of its lead compound Fovista, an anti-platelet-derived growth factor (PDG...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Ophthotech Corp. is a privately held biopharmaceutical company based in Princeton, NJ and New York, NY focused on developing and commercializing therapies for back-of-the-eye diseases. Ophthotech plan...
Ophthotech Corporation is a privately held biopharmaceutical company based in Princeton, NJ focused on developing and commercializing therapies for dry and wet AMD. Ophthotech is...
More Information about "Ophthotech Corporation" on BioPortfolio
We have published hundreds of Ophthotech Corporation news stories on BioPortfolio along with dozens of Ophthotech Corporation Clinical Trials and PubMed Articles about Ophthotech Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ophthotech Corporation Companies in our database. You can also find out about relevant Ophthotech Corporation Drugs and Medications on this site too.
